PBX1 and acute lymphoblastic leukemia: While TCF3-PBX1 ALL was formerly linked to an intermediate or unfavorable prognosis, modern therapeutic regimens have enhanced outcome; thus, TCF3-PBX1 fusion is no longer considered for risk stratification [28].